NGM707 was captured on Protein-A surface. Human ILT4 (1.56-200nM) was injected to. Figure 5. NGM707 is a Potent Inhibitor of Both ILT2 and ILT4 Interactions with MHC-I. Figure 10. ILT2 Blockade Enhances Primary NK Cell Killing Activity. Figure 11. ILT2 and ILT4 Blockade Act Additively to Enhance Dendritic Cell Fc-mediated Activation. Figure 12.

We now report the preclinical characterization of NGM831, a humanized IgG1 (N297G) antibody that binds to ILT3 of human and cynomolgus monkey origin with high specificity and sub-nM affinity and blocks the interaction of ILT3 with both its reported ligands, fibronectin and ApoE.

NGM707-IO-101 (NCT04913337) is a first-in-human Phase 1/2 clinical trial of NGM707 monotherapy and combination with pembrolizumab. Here we report pharmacodynamic and predictive biomarker data from NGM707-IO-101 monotherapy and …

2024年4月5日 · CONCLUSIONS: NGM707 in combination with pembrolizumab appears to be safe and well tolerated at all dose levels. In this advanced and metastatic solid tumor cohort, early efficacy signals have been observed. Preliminary evidence of myeloid cell reprogramming was observed in paired tumor biopsies.

2022年6月15日 · We now report the pre-clinical characterization of NGM831, a humanized IgG1 (N297G) antibody that binds to ILT3 of human and cynomolgus monkey origin with high specificity and sub-nM affinity and blocks the interaction of ILT3 with both its …

2021年7月1日 · NGM707 is a humanized monoclonal antibody with specificity for both ILT2 and ILT4, blocking their interaction with both classical MHC-I (HLA-A, HLA-B, HLA-C) as well as the non-classical MHC-I molecule HLA-G. We present here preclinical data on …

2024年3月19日 · NGM Bio’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights...

2024年3月19日 · NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held ...

NGM Biopharmaceuticals, South San Francisco, CA, USA. Background: NGM707-IO-101 (NCT04913337) is a Phase 1/2, dose escalation/expansion study evaluating NGM707, a humanized monoclonal antibody that blocks ILT2 and ILT4 receptors, as monotherapy or in combination with pembrolizumab. Here we report dat a from the combination Part 1b of the study.

Conclusions: NGM707 as monotherapy and in com-bination with pembrolizumab wassafe and well tolerated at all dose levels. In heavily pretreated advanced and metastatic solid tumor malignancies, we observed early efficacy and biomarker signals, including in tumors considered unresponsive to anti-PD(L)1.